respiratory syncytial virus monoclonal antibody (palivizumab), intramuscular

Known as: RSV-MAb 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2017
0119892017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Antibody-based drugs have attracted much attention for their targeting ability, high efficacy and low toxicity. But it is… (More)
Is this relevant?
2006
2006
Treatment of malignant glioma is therapeutically challenging. Despite improvements in neurosurgery, radiotherapy and chemotherapy… (More)
Is this relevant?
2005
2005
5-Fluorouracil (5-FU) and human recombinant y-interferon (y-IFN) were found to increase the expression of carcinoembryonic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1996
1996
Astrocytes exhibit a diverse morphology and numerous functions in the central nervous system as well as in the retina. In order… (More)
Is this relevant?
1995
1995
Reshaped human MAb RSHZ19, which is specific for the surface fusion protein of respiratory syncytial virus (RSV) is in clinical… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1993
1993
The reactivity of five anti-human rotavirus VP4 neutralizing monoclonal antibodies (N-mAb) with 20 animal rotavirus strains and… (More)
Is this relevant?
1989
1989
Using murine monoclonal antibodies (MAbs) raised against the common antigen of group A rotavirus (RV), two single-sandwich ELISA… (More)
Is this relevant?